MedTrace Logo

Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent

NCT02689713 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-12-17

No results posted yet for this study

Summary

This study seeks to test if the study drug (voriconazole), when applied topically to a burn wound on the skin will help to reduce pain.

Conditions

  • Pain
  • Thermal Injury
  • Burns
  • Hyperalgesia

Interventions

DRUG

Voriconazole (topical)

The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.

DRUG

Topical Sterile Water Placebo Group

Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.

Sponsors & Collaborators

  • San Antonio Military Medical Center

    collaborator FED

  • U.S. Army Medical Research and Development Command

    collaborator FED

  • Kenneth Hargreaves

    lead OTHER

Principal Investigators

  • Christopher E White, MD · Brook Army Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-15
Primary Completion
2018-11-14
Completion
2018-11-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02689713 on ClinicalTrials.gov